Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 14/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 13/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031078 | 1.00 | EPHX2 (0.57) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 | |
| SCHEMBL5527766 | 0.93 | EPHX2 (0.66) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 | |
| SCHEMBL5527771 | 0.93 | EPHX2 (0.66) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 | |
| SCHEMBL4027345 | 0.90 | MCHR1 (0.61) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 | |
| SCHEMBL4027350 | 0.90 | MCHR1 (0.61) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 | |
| SCHEMBL4029653 | 0.88 | MCHR1 (0.56) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 | |
| SCHEMBL4029656 | 0.88 | MCHR1 (0.56) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 | |
| SCHEMBL13797424 | 0.87 | MCHR1 (0.61) | MCHR1ADRA2ANPY5RHTR1AADRA1A | |
| SCHEMBL5523146 | 0.87 | MCHR1 (0.64) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 | |
| SCHEMBL5523138 | 0.87 | MCHR1 (0.64) | EPHX2CYP3A4CYP2C9CYP2D6MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611109-A4 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-24 | — | — | EP | claimed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | claimed |
| JP-2006522109-A | — | — | 2006-09-28 | — | — | JP | claimed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | claimed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | EPHX2 3017/4885CYP3A4 334/4885CYP2C9 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.